Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...

North Chicago-based Abbott announced last month it reached a settlement agreement with Dexcom over all outstanding patent disputes relating to their glucose monitoring products, which estimate ...

Dexcom (Nasdaq:DXCM) announced today that it plans to establish a direct presence in Italy, bringing its CGM technology to ...

An Apple Watch, which integrates easily into the Dexcom CGM ecosystem ... Until then, if you need a primer on continuous glucose monitoring, we’re happy to oblige.

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

DexCom develops continuous glucose monitoring (CGM) devices that help diabetes patients track their sugar levels constantly, allowing them to make better decisions for their health. DexCom's ...

Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM ... domestic CGM market in the US to reach $7.8 billion in 2025 and more than $10 billion ...

Redburn Atlantic upgraded DexCom (DXCM) to Buy from Neutral with a price target of $115, up from $85. The company is positioned to benefit from ...

SAN FRANCISCO—After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have diabetes, Dexcom said it expects to see more than $4.03 ...